---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-006001"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:55:18.397881+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Xenetic Biosciences Q2 2025 net loss $0.7M; cash $4.8M; expands Scripps partnership

## Summary
- Net loss ~$0.7M for Q2 2025; no revenue reported.
- R&D expenses fell 29.7% to ~$0.7M; G&A down 41.8% to ~$0.7M vs Q2 2024.
- Cash at quarter-end ~$4.8M to fund operations.
- Expanded collaboration with Scripps Research Institute for DNase I plus CAR T-cell studies.
- Partner PeriNess commenced patient dosing in pancreatic cancer study; exploratory CAR T study in large B cell lymphoma.

## SEC filing metadata
- accession: 0001683168-25-006001
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316825006001/0001683168-25-006001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316825006001/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-006001
- JSON: https://secwatch.observer/filing/0001683168-25-006001.json
- Plain text: https://secwatch.observer/filing/0001683168-25-006001.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.